Post by
enriquesuave on Aug 13, 2021 2:59pm
Competition waiting on FDA approval
SESN has been running up lately and now sits at a $1.2 Billion Market Cap now at around $6 per share. Was around 60-80 cents 12-24 months ago. FDA decision date August 18. Durable efficacy of 17% CR rate at 12 months mark after 36 instillations of Vicinium. We need more data, but when we do it will be easy to compare and evaluate what our MC should be. Hopefully closer to a $Billion than where we are now. IMO
Comment by
enriquesuave on Aug 13, 2021 3:12pm
Holy Sh. SESN tanked on FDA CRL.
Comment by
enriquesuave on Aug 13, 2021 3:19pm
SESN hit its yearly high of 6.04 today and yearly low of 0.70 following CRL from FDA. Maybe they know we have the goods and no one else compares. Just saying. All IMO. Feel sorry for SESN shareholders
Comment by
menoalittle on Aug 13, 2021 3:50pm
>> Maybe they know we have the goods and no one else compares. That was my very first thought when I read the CRL... that perhaps the FDA has considered (and maybe knows something more than) what we know (or maybe I should say, strongly suspect.)
Comment by
menoalittle on Aug 13, 2021 3:55pm
appears to be extremely thinly traded relative to the ~172 million shares outstanding
Comment by
baystock1 on Aug 13, 2021 3:51pm
SESN market cap is still 10X that of TLT. Somebody with deep pockets could short SESN and buy TLT on the theory that the market caps should converge.
Comment by
Eoganacht on Aug 13, 2021 7:36pm
I'm fairly confident that Theralase will do far better than Viciniums's less than 17% CR rate at 12 months. Maybe even 4 times better.
Comment by
Oilminerdeluxe on Aug 14, 2021 10:30am
What does Sesen have besides this now (failed?) drug? I read something about head and neck cancer. One can at least have high hopes TLT should be better than they at 12 months. And Sesen still has a market cap waaaay beyond TLT. Interesting. Hm, maybe TLT was waiting for this happening to occur.
Comment by
DJDawg on Aug 13, 2021 3:56pm
Wow. I had some options on SESN that just sold for a small profit yesterday. So lucky. random luck. Incidentally, our drug candidate wouldn't be in a BLA application pipeline as far as I can see. Not a protein or immunotherapy? Seems BLA's have much bigger approval challenges around production quality. Correct?
Comment by
Pandora on Aug 13, 2021 8:56pm
SESN closed yesterday at $4.91 and today opened at $5.22 U.S. - hit a high of $6.04 and then a low of $0.70 before closing at $2.11. Buying at $0.70 might have been good - not sure I would have wanted to be in the other part of it. The ups and downs of FDA decisions - wow!